Commerce Bank Takes Position in Illumina, Inc. $ILMN

Commerce Bank purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 8,959 shares of the life sciences company’s stock, valued at approximately $1,575,000.

Other large investors also recently modified their holdings of the company. HighPoint Advisor Group LLC raised its holdings in Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after acquiring an additional 80 shares in the last quarter. Elevation Wealth Partners LLC grew its stake in Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares in the last quarter. Meeder Advisory Services Inc. increased its position in shares of Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after purchasing an additional 85 shares during the last quarter. Toronto Dominion Bank increased its position in shares of Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after purchasing an additional 92 shares during the last quarter. Finally, Panagora Asset Management Inc. raised its stake in shares of Illumina by 3.9% during the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after purchasing an additional 96 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Up 0.8%

Shares of NASDAQ ILMN opened at $224.99 on Wednesday. The stock has a market capitalization of $33.97 billion, a P/E ratio of 41.98, a PEG ratio of 3.14 and a beta of 1.45. The stock’s fifty day moving average is $190.35 and its 200 day moving average is $153.78. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $226.84. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the company posted $1.19 earnings per share. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ILMN shares. Canaccord Genuity Group upped their price target on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. TD Cowen boosted their price objective on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. Barclays upped their target price on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. Guggenheim raised their target price on shares of Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. lifted their price target on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $188.40.

Insider Activity

In related news, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 2,095,958 shares of company stock worth $401,720,974. Insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.